Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abipapogene suvaplasmid - Nykode Therapeutics

Next Previous
Drug Profile

Abipapogene suvaplasmid - Nykode Therapeutics

Alternative Names: Abi-suva; VB 10.16; VB1016

Latest Information Update: 29 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vaccibody
  • Developer Merck & Co; Nykode Therapeutics; Roche
  • Class Antineoplastics; Cancer vaccines; DNA vaccines; Papillomavirus vaccines; Recombinant fusion proteins
  • Mechanism of Action Antigen presenting cell modulators; B cell stimulants; Immunologic cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Cervical cancer; Squamous cell cancer
  • Phase I/II Cervical intraepithelial neoplasia

Most Recent Events

  • 16 Oct 2025 Phase-II clinical trials in Squamous cell cancer (Combination therapy, Recurrent, Metastatic disease, First-line therapy) (IM) (Nykode Therapeutics pipeline, October 2025)
  • 30 May 2025 Efficacy data from a phase II trial in Cervical cancer presented at the 61st Annual Meeting of the American Society of Clinical Oncology (ASCO 2025)
  • 08 Jan 2025 Updated efficacy data from a phase II trial in Cervical cancer released by Nykode Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top